SNIPR Biome’s data on first clinical drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology

Avatar photo
Business Intelligence

SNIPR001 is a novel CRISPR-Cas therapeutic designed to selectively target antibiotic resistant E. coli, which can cause fatal infections in vulnerable hematological cancer patients            SNIPR001 represents the first CRISPR- therapeutic developed to specifically remove E. coli in the human gut            In vitro studies showed SNIPR001 displaying high specificity towards E. coli and activity in multi-drug resistant strains

COPENHAGEN, Denmark, May 5, 2023 /PRNewswire/ —  SNIPR Biome ApS (“SNIPR”), the company pioneering CRISPR-based microbial gene therapy, announces today that Nature Biotechnology has published research findings from its preclinical work on  SNIPR001, the first CRISPR-armed phage therapeutic developed to specifically target and remove E. coli, including antibiotic-resistant strains, in the human gastrointestinal tract.

The emergence of antibiotic-resistant pathogens represents a major global challenge. In numerous disease areas, current medical practice relies on increasingly aggressive therapies, which can sometimes result in patients experiencing life-threatening infections, including those caused by antibiotic-resistant bacteria. This issue is often under-recognized in contemporary healthcare ecosystems and the escalating threat of antimicrobial resistance has the potential to lead to a significant health care challenge in the future.

SNIPR001’s mechanism of action, as a CRISPR-armed phage therapeutic that specifically targets and eradicates E. coli in the gut, is designed to prevent infections from spreading into the bloodstream and represents a promising advancement against antibiotic-resistant pathogens. This publication represents a significant validation of the ground-breaking technology research done at the laboratories and collaborators of SNIPR Biome and also opens up the possibility of targeting other pathogens.

Dr Christian Grøndahl CEO and co-founder of SNIPR Biome, commented: “This therapy has the potential to revolutionize the way we prevent and treat infections, and we believe it could potentially serve as a model for developing similar therapies that target other life-threatening pathogens. By integrating different aspects of drug development, from bioinformatics to regulatory requirements, we have been able to leverage our CRISPR-Cas technology to generate a whole new class of drugs.”

 Dr Eric van der Helm VP of Scientific Affairs of SNIPR Biome, commented:  “This article represents a true team effort over the last few years of many of our employees and collaborators to integrate all aspects of drug development ranging from bioinformatics, synthetic biology, in vitro assays, in vivo models to regulatory requirements and CMC. With more than a million deaths annually attributed to antimicrobial resistance, we are committed to developing precision medicines that will make a significant impact in the fight against this global health threat.”

 SNIPR001 has been granted a Fast-Track designation by the US Food and Drug Administration (“FDA”), was supported by CARB-X, and SNIPR is currently conducting a Phase 1 trial in the US to evaluate its safety and efficacy in reducing E. coli in the gut without disturbing the overall gut microbiome (NCT05277350).

Article citation: Gencay, Y.E., Jasinskytė, D., Robert, C. et al. Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice. Nat Biotechnol (2023). https://www.nature.com/articles/s41587-023-01759-y

CONTACT:

SNIPR Biome
Dr Christian Grøndahl, Co-founder and CEO
E-mail: [email protected] 
Mobile: +45 20202747 
www.sniprbiome.com 
Please follow us on LinkedIn & Twitter: @SNIPRBiome

Consilium Strategic Communications
Tracy Cheung, Chris Welsh, Davide Salvi
Tel: +44 (0) 203 709 5700
[email protected]

View original content:https://www.prnewswire.com/apac/news-releases/snipr-biomes-data-on-first-clinical-drug-candidate-to-prevent-infections-in-hematological-cancer-patients-published-in-nature-biotechnology-301816381.html

SOURCE SNIPR Biome ApS

相關文章

澳門大學預測2024年澳門GDP增長16.8%

澳門大學發表2024年澳門宏觀經濟修訂預測,預計澳門今年地區生產總值增長16.8%,恢復至2019年水平的94.5%。

澳門2月新批核住宅按揭及商用物業貸款均下跌

澳門金融管理局4月11日發佈的統計數據顯示,2024年2月新批核的住宅按揭貸款按月下跌 42.5%至 6.9 億澳門元。

第十二屆旅博會將於4月26日揭幕

第十二屆澳門國際旅遊(產業)博覽會將於4月26日至28日舉行,今屆旅博會以“相匯旅博 相聚商機”為口號,招聚海內外旅遊及相關業者來澳參與。截至目前,參展商有超過600家,買家約500位,展位超過1,300個。

探索線上演唱會動態

澳門旅遊學院研究人員探討消費者決定“參與”線上演唱會的動機,並為優化此類活動提供了指引。 

澳門總體失業率維持2.2%,本地居民失業率為2.8%

澳門統計暨普查局資料顯示,2023年12月至2024年2月期間,澳門總體失業率為2.2%,本地居民失業率為2.8%。

澳門2月綜合物價按年升1.46%

統計暨普查局表示部份升幅是由於今年農曆新年在2月,而去年則在1月,物價在農曆新年期間普遍較高所引致。